Please login to the form below

Not currently logged in


This page shows the latest ATMPs news and features for those working in and with pharma, biotech and healthcare.

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Merk &Kollegen, which will give it access to the latter’s advanced therapy medicinal products (ATMP)-based immuno-oncology therapies. ... Merk &Kollegen’s manufacturing site, which is involved in ATMP-based cancer immunology treatments.

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • EU cross-border healthcare EU cross-border healthcare

    The reality for many patients and their families is sobering. Gene therapies and other Advanced Therapy Medicinal Products (ATMPs) require specialist treatment processes. ... The current challenges patients face when seeking access to an approved gene

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    177 requests for eligibility, or 8 a month on average. 71 requests have been chemical products, 43 biological, 42 ATMPs with the last 13 classed as ‘other’.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

  • Gathering pace: adaptive pathways Gathering pace: adaptive pathways

    Applications included six advanced-therapy medicinal products (ATMPs) and 12 orphan drugs, while 14 of them were for new cancer therapies. ... The first of these in-depth discussions, on the quality aspects of an ATMP, took place in December 2014, with

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • EU Pharmaceutical Strategy Roadmap EU Pharmaceutical Strategy Roadmap

    In ATMPs, the need for surveillance and long-term follow-up of patients will need to be addressed. ... And we continue to see the pricing and reimbursement challenges faced by ATMPs.

  • Hanover Communications Hanover Communications

    As discussed in a recent article, the next few years will define the future of life sciences and especially the regulation of breakthrough advanced therapy medicinal products (ATMPs) and orphan medicinal ... ATMPs and OMPs.

  • Spotlight interview: 15 minutes on healthcare communications in gene therapy

    It is an exciting and interesting time with many ATMPs being launched over the next few years. ... 3. WHAT EXPERIENCE HAS OPEN HEALTH HAD WITH ATMP COMMERCIALISATION? We have worked with around half of the ATMPs that have already been launched globally.

  • Generating data on long-term outcomes with gene and other advanced therapies

    From a patient perspective, and if ATMPs fulfil their promise, post-treatment disease symptoms may be considerably reduced or even non-existent. ... From a health system perspective, it is likely that ATMPs will continue to be introduced in a small

  • Event: World Pharma Pricing and Market Access Congress

    A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...